Skip to Content

Daratumumab

In the US, Daratumumab (daratumumab systemic) is a member of the drug class CD38 monoclonal antibodies and is used to treat Multiple Myeloma.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XC24

CAS registry number (Chemical Abstracts Service)

0945721-28-8

Chemical Formula

C6466-H9996-N1724-O2010-S42

Molecular Weight

145390

Therapeutic Categories

Cytostatic agent

Antineoplastic agent: Monoclonal antibody

Chemical Name

Immunoglobulin G1-kappa, anti-[Homo sapiensADP-ribosyl cyclase 1 (CD38, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10)], Homo sapiensmonoclonal antibody;Gamma1 haevy chain (1-452) [Homo sapiensVH (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.15] (1 (WHO)

Foreign Names

  • Daratumumabum (Latin)
  • Daratumumab (German)
  • Daratumumab (French)
  • Daratumumab (Spanish)

Generic Names

  • Daratumumab (OS: USAN)
  • HuMax-CD38 (IS)
  • UNII-4Z63YK6E0E (IS)

Brand Name

  • DARZALEX
    Janssen Biotech, United States

International Drug Name Search

Glossary

TermDefinition
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide